BMS, Celldex combine cancer immunotherapies; BMS has negotiation rights to varlilumab
Executive Summary
In a Phase I/II trial that’s slated to begin in Q4 2014, Bristol-Myers Squibb Co. and Celldex Therapeutics Inc. (antibodies, antibody-drug conjugates, and vaccines that act as immunomodulators) agreed to study the safety, tolerability, and preliminary efficacy of a combination of their cancer immunotherapeutics--BMS’s PD-1 immune checkpoint inhibitor nivolumab with Celldex’s CD27 antagonist varlilumab--against multiple tumors, including non-small cell lung cancer, metastatic melanoma, ovarian, colorectal, and squamous cell head and neck.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
- Trial Collaborations
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice